US High Growth Tech Stocks To Watch In July 2026
Over the last 7 days, the United States market has experienced a 2.6% drop, yet it remains up by 14% over the past year with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying high growth tech stocks involves evaluating companies that demonstrate strong innovation and adaptability to capitalize on evolving market trends.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| AppLovin | 21.14% | 21.74% | ★★★★★★ |
| Fabrinet | 20.12% | 22.27% | ★★★★★★ |
| Krystal Biotech | 29.71% | 35.79% | ★★★★★★ |
| Lumentum Holdings | 42.94% | 56.54% | ★★★★★★ |
| Super Micro Computer | 24.16% | 22.40% | ★★★★★★ |
| AnaptysBio | 20.47% | 48.14% | ★★★★★★ |
| Marker Therapeutics | 64.28% | 69.04% | ★★★★★★ |
| Syndax Pharmaceuticals | 28.32% | 68.06% | ★★★★★★ |
| Madrigal Pharmaceuticals | 28.70% | 59.24% | ★★★★★★ |
| Travere Therapeutics | 23.50% | 50.79% | ★★★★★★ |
Click here to see the full list of 20 stocks from our US High Growth Tech and AI Stocks screener.
We'll examine a selection from our screener results.
Krystal Biotech (KRYS)
Simply Wall St Growth Rating: ★★★★★★
Overview: Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines to address diseases with high unmet medical needs in the United States, with a market capitalization of approximately $10.74 billion.
Operations: Krystal Biotech generates revenue primarily from its activities in discovering, developing, manufacturing, and commercializing genetic medicines, with reported revenue of $417.30 million. The company is positioned within the biotechnology sector and operates exclusively in the United States to address diseases with high unmet medical needs.
Krystal Biotech, a trailblazer in gene therapy for dermatological diseases, has shown remarkable growth with an 81.5% increase in earnings over the past year, outpacing the biotech industry's 64.1%. This surge is underpinned by robust R&D investments aimed at pioneering treatments like KB801 for neurotrophic keratitis. Recent approvals, such as VYJUVEK in the UK for treating dystrophic epidermolysis bullosa, underscore its commitment to addressing rare genetic disorders. Despite dropping from the S&P 600 Health Care Sector, Krystal was added to the S&P 400, reflecting its evolving market stature and investor confidence fueled by a forecasted annual earnings growth of 35.8% and revenue growth of 29.7%.
- Unlock comprehensive insights into our analysis of Krystal Biotech stock in this health report.
Examine Krystal Biotech's past performance report to understand how it has performed in the past.
Palantir Technologies (PLTR)
Simply Wall St Growth Rating: ★★★★★★
Overview: Palantir Technologies Inc. develops software platforms for intelligence agencies to support counterterrorism efforts globally, with a market cap of approximately $296.14 billion.
Operations: Palantir Technologies generates revenue through two primary segments: Commercial, which contributed $2.45 billion, and Government, with $2.77 billion in revenue. The company focuses on building software platforms that aid intelligence agencies in counterterrorism operations across various regions, including the U.S. and the U.K.
Palantir Technologies has demonstrated a robust integration of its AI and data analytics capabilities into diverse sectors, significantly enhancing operational efficiencies and fraud detection. Recently, the U.S. Small Business Administration deployed Palantir's software to bolster its anti-fraud initiatives across pandemic-era relief programs, showcasing the company's pivotal role in governmental operations. This strategic application aligns with Palantir’s 30.9% annual revenue growth and underscores its deepening penetration in critical public sector activities, further evidenced by a 31.9% surge in earnings annually. The firm's commitment to innovation is marked by substantial R&D investments amounting to $1 billion last year alone, positioning it as a key enabler of advanced data solutions in both government and private sectors.
- Click here and access our complete health analysis report to understand the dynamics of Palantir Technologies.
Gain insights into Palantir Technologies' past trends and performance with our Past report.
Western Digital (WDC)
Simply Wall St Growth Rating: ★★★★★★
Overview: Western Digital Corporation is a global company that specializes in the development, manufacturing, and sale of data storage devices and solutions using hard disk drive technology, with a market cap of approximately $159.76 billion.
Operations: The company generates revenue primarily from the sale of hard disk drives (HDD), amounting to $11.78 billion.
Amidst a dynamic tech landscape, Western Digital stands out with its strategic maneuvers and robust R&D commitment. The company's recent merger discussions with Kioxia could significantly enhance its position in the NAND flash sector, crucial for data-center and PC memory markets. This move follows a series of index adjustments, reflecting a nuanced market perception. Innovatively, at Computex 2026, Western Digital underscored its pivotal role in AI infrastructure by demonstrating advanced HDD technologies and storage solutions tailored for escalating data demands. These efforts are complemented by an aggressive R&D expenditure strategy that not only fuels innovation but also aligns with industry shifts towards more sophisticated data management systems.
Where To Now?
- Click here to access our complete index of 20 US High Growth Tech and AI Stocks.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com